Allarity Therapeutics Europe ApS - CVR: 34623562

2022, DKK

02.07.2023

Bruttoresultat

-42.967'

Primær drift

-170''

Årets resultat

-142''

Aktiver

366''

Kortfristede aktiver

15.980'

Egenkapital

244''

Afkastningsgrad

-47 %

Soliditetsgrad

67 %

Likviditetsgrad

15 %

Resultat

02.07.2023

Årsrapport	2022 02.07.2023	2021 27.07.2022	2020 05.07.2021	2019 26.06.2020	2018 12.06.2019	2017 19.06.2018	2016 07.06.2017	2015 28.05.2016
Nettoomsætning
Bruttoresultat	-42.967.000	-79.617.000	-13.158.000	-27.706.000	-40.913.000	-32.986.246	-26.150.595	-6.346.465
Resultat af primær drift	-170.425.000	-79.974.000	-16.910.000	-39.123.000	-46.651.000	-38.449.763	-28.595.578	-6.726.150
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	0	3.735.000	6.952.000	4.238.000	5.153.000	2.739.266	716.603	0
Finansieringsomkostninger	-3.222.000	-4.616.000	-10.949.000	-4.057.000	-3.464.000	-13.392.643	-692.193	-595.611
Andre finansielle omkostninger	0	0	0	0	0	0	0	-595.611
Resultat før skat	-173.647.000	-43.654.000	-20.907.000	-38.942.000	-34.098.000	-49.103.140	-28.571.168	-7.321.761
Resultat	-142.438.000	-76.279.000	-18.557.000	-33.965.000	-30.821.000	-43.604.140	-23.071.168	-7.321.761
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

02.07.2023

Årsrapport	2022 02.07.2023	2021 27.07.2022	2020 05.07.2021	2019 26.06.2020	2018 12.06.2019	2017 19.06.2018	2016 07.06.2017	2015 28.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	6.919.261	245.811	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	13.664.000	15.876.000	18.579.000	15.954.000	12.825.000	9.069.684	16.067.680	3.686.505
Likvider	2.316.000	12.717.000	100.000	5.607.000	19.000	6.260.907	14.688.300	13.602.184
Kortfristede aktiver	15.980.000	30.891.000	18.679.000	21.561.000	12.844.000	22.249.852	31.001.791	17.288.689
Immaterielle aktiver og goodwill	348.827.000	467.500.000	10.554.000	9.682.000	16.245.000	22.118.406	1.126.326	1.369.041
Finansielle anlægsaktiver	951.000	349.000	8.869.000	8.864.000	3.551.000	0	0	0
Materielle aktiver	185.000	52.000	68.000	173.000	248.000	366.614	485.623	0
Langfristede aktiver	349.963.000	467.901.000	19.491.000	18.719.000	20.044.000	22.725.818	1.812.747	1.369.041
Aktiver	365.943.000	498.792.000	38.170.000	40.280.000	32.888.000	44.975.670	32.814.538	18.657.730

Aktiver

02.07.2023

Passiver

02.07.2023

Årsrapport	2022 02.07.2023	2021 27.07.2022	2020 05.07.2021	2019 26.06.2020	2018 12.06.2019	2017 19.06.2018	2016 07.06.2017	2015 28.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	243.758.000	386.284.000	-147.061.000	-128.504.000	-94.539.000	-63.718.661	-20.114.521	1.282.966
Hensatte forpligtelser	12.415.000	38.522.000	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	39.433.000	52.378.000	12.549.000	10.845.000	5.608.000	4.735.265	4.216.358	0
Kortfristede forpligtelser	109.770.000	67.563.000	14.182.000	70.874.000	28.976.000	34.579.566	8.578.204	2.499.638
Gældsforpligtelser	109.770.000	73.986.000	185.231.000	168.784.000	127.427.000	108.694.331	52.929.059	17.374.764
Forpligtelser	109.770.000	73.986.000	185.231.000	168.784.000	127.427.000	108.694.331	52.929.059	17.374.764
Passiver	365.943.000	498.792.000	38.170.000	40.280.000	32.888.000	44.975.670	32.814.538	18.657.730

Passiver

02.07.2023

Nøgletal

02.07.2023

Årsrapport	2022 02.07.2023	2021 27.07.2022	2020 05.07.2021	2019 26.06.2020	2018 12.06.2019	2017 19.06.2018	2016 07.06.2017	2015 28.05.2016
Afkastningsgrad	-46,6 %	-16,0 %	-44,3 %	-97,1 %	-141,8 %	-85,5 %	-87,1 %	-36,1 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-58,4 %	-19,7 %	12,6 %	26,4 %	32,6 %	68,4 %	114,7 %	-570,7 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-5.289,4 %	-1.732,5 %	-154,4 %	-964,3 %	-1.346,7 %	-287,1 %	-4.131,2 %	-1.129,3 %
Soliditestgrad	66,6 %	77,4 %	-385,3 %	-319,0 %	-287,5 %	-141,7 %	-61,3 %	6,9 %
Likviditetsgrad	14,6 %	45,7 %	131,7 %	30,4 %	44,3 %	64,3 %	361,4 %	691,6 %

Resultat

02.07.2023

Gæld

02.07.2023

Årsrapport

02.07.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 02.07.2023)

Information om virksomhedens regnskabsklasse:The annual report of Allarity Therapeutics Europe ApS for 2022 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B and the Accounting Standard on small enterprises. The accounting policies applied are consistent with those of last year. The annual report for 2022 is presented in DKK.

Beretning

02.07.2023

Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertainties In the financial statements for the financial year 01. 01. 22 - 31. 12. 22, it is important to note the following uncertainty with regard to recognition and measurement, as it has had a significant influence on the assets and liabilities recognised in the financial statements: On 20 December 2021, the Company acquired DRP technology and IP rights from Allarity Therapeutics A/S together with employees and other assets and liabilities. The acquired business was valued based on the market value of Allarity Therapeutics in December 2021. The market value of Allarity Therapeutics has declined significantly in 2022, which resulted in an impairment charge in 2022.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The executive board has today discussed and approved the annual report of Allarity Therapeutics Europe ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business review The Company is a wholly owned subsidiary of Allarity Therapeutics, Inc. , a Delaware, United States incorporated Company listed on NASDAQ, in the United States of America. Allarity Therapeutics, Inc. is the parent company (“Parent Company”) which owns 100% of Allarity Therapeutics Europe ApS and 100% of Allarity Therapeutics Denmark ApS (collectively referred to as the “Group” or the “Allarity Group”. The Company's activities comprise drug development dedicated to unlocking the potential of new and failed oncology products in order to improve the efficacy of the drugs increase the response rate in cancer patients, reduce timelines and through this improve success rates in oncology drug development.